TABLE 1 GLOBAL ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021- 2030 (USD MILLION)
TABLE 2 GLOBAL INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 31 GLOBAL VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 GLOBAL DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 33 GLOBAL HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 GLOBAL DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 35 GLOBAL RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 GLOBAL RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 37 GLOBAL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 38 GLOBAL FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 39 GLOBAL CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 GLOBAL OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 GLOBAL ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)
TABLE 42 GLOBAL GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 GLOBAL GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 44 GLOBAL CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 GLOBAL CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 46 GLOBAL ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 GLOBAL ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 48 GLOBAL ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)
TABLE 49 GLOBAL ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 GLOBAL ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 51 GLOBAL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 52 GLOBAL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 53 GLOBAL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 54 GLOBAL TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 55 GLOBAL TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 56 GLOBAL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 57 GLOBAL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 58 GLOBAL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 59 GLOBAL PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 GLOBAL PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 GLOBAL NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 GLOBAL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)
TABLE 64 GLOBAL ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)
TABLE 65 GLOBAL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)
TABLE 66 GLOBAL ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 82 NORTH AMERICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 NORTH AMERICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 84 NORTH AMERICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 85 NORTH AMERICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 86 NORTH AMERICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 87 NORTH AMERICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 88 NORTH AMERICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 NORTH AMERICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 NORTH AMERICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 91 NORTH AMERICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 92 NORTH AMERICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 93 NORTH AMERICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 94 NORTH AMERICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 95 NORTH AMERICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 96 NORTH AMERICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 97 NORTH AMERICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 98 NORTH AMERICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 99 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 100 NORTH AMERICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 101 NORTH AMERICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 102 NORTH AMERICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 103 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 NORTH AMERICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 NORTH AMERICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 NORTH AMERICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 NORTH AMERICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 NORTH AMERICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 NORTH AMERICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 NORTH AMERICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 NORTH AMERICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 NORTH AMERICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 113 NORTH AMERICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 114 NORTH AMERICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 115 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 116 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 117 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 118 U.S. ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 119 U.S. INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 U.S. NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 121 U.S. M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 122 U.S. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 123 U.S. HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 124 U.S. REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 125 U.S. NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 126 U.S. NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 127 U.S. INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 128 U.S. NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 129 U.S. INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 130 U.S. GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 131 U.S. PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 132 U.S. HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 133 U.S. NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 U.S. NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 U.S. NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 136 U.S. NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 137 U.S. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 138 U.S. MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 139 U.S. HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 140 U.S. DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 141 U.S. ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 142 U.S. HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 143 U.S. VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 144 U.S. DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 145 U.S. RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 146 U.S. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 147 U.S. FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 148 U.S. ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 149 U.S. GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 150 U.S. CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 151 U.S. ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 152 U.S. ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 153 U.S. ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 154 U.S. SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 155 U.S. SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 U.S. LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 U.S. TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 U.S. SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 U.S. LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 U.S. SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 U.S. PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 U.S.CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 163 U.S. NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 164 U.S. ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 165 U.S. ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 166 U.S. ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 167 CANADA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 168 CANADA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 169 CANADA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 170 CANADA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 171 CANADA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 172 CANADA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 173 CANADA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 174 CANADA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 175 CANADA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 176 CANADA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 177 CANADA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 CANADA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 CANADA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 CANADA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 181 CANADA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 182 CANADA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 183 CANADA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 184 CANADA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 185 CANADA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 186 CANADA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 187 CANADA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 188 CANADA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 189 CANADA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 190 CANADA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 191 CANADA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 192 CANADA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 193 CANADA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 194 CANADA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 CANADA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 196 CANADA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 197 CANADA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 198 CANADA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 199 CANADA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 200 CANADA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 CANADA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 CANADA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 CANADA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 CANADA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 CANADA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 CANADA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 CANADA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 CANADA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 209 CANADA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 210 CANADA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 211 CANADA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 212 CANADA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 213 CANADA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 214 CANADA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 215 MEXICO ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 216 MEXICO INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 217 MEXICO NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 218 MEXICO M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 219 MEXICO RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 220 MEXICO HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 221 MEXICO REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 222 MEXICO NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 223 MEXICO NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 224 MEXICO INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 MEXICO NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 226 MEXICO INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 227 MEXICO GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 228 MEXICO PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 229 MEXICO HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 230 MEXICO NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 231 MEXICO NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 232 MEXICO NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 233 MEXICO NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 234 MEXICO RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 235 MEXICO MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 236 MEXICO HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 237 MEXICO DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 238 MEXICO ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 MEXICO HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 MEXICO VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 241 MEXICO DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 242 MEXICO RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 MEXICO RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 244 MEXICO FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 245 MEXICO ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 246 MEXICO GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 247 MEXICO CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 248 MEXICO ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 249 MEXICO ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 250 MEXICO ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 251 MEXICO SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 MEXICO SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 MEXICO LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 MEXICO TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 MEXICO SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 MEXICO LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 MEXICO SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 MEXICO PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 MEXICO CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 MEXICO NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 261 MEXICO ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 262 MEXICO ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 263 MEXICO ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 264 EUROPE ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 265 EUROPE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 266 EUROPE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 267 EUROPE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 EUROPE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 EUROPE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 271 EUROPE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 272 EUROPE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 273 EUROPE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 274 EUROPE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 EUROPE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 276 EUROPE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 277 EUROPE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 278 EUROPE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 279 EUROPE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 280 EUROPE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 281 EUROPE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 282 EUROPE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 283 EUROPE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 284 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 EUROPE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 286 EUROPE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 287 EUROPE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 288 EUROPE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 289 EUROPE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 290 EUROPE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 291 EUROPE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 292 EUROPE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 293 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 294 EUROPE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 295 EUROPE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 296 EUROPE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 297 EUROPE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 298 EUROPE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 299 EUROPE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 300 EUROPE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 301 EUROPE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 302 EUROPE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 303 EUROPE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 304 EUROPE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 305 EUROPE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 306 EUROPE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 307 EUROPE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 308 EUROPE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 309 EUROPE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 310 EUROPE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 311 EUROPE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 312 EUROPE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 313 EUROPE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 314 GERMANY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 315 GERMANY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 316 GERMANY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 GERMANY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 318 GERMANY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 319 GERMANY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 320 GERMANY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 321 GERMANY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 322 GERMANY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 323 GERMANY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 324 GERMANY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 325 GERMANY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 326 GERMANY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 327 GERMANY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 GERMANY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 GERMANY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 330 GERMANY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 331 GERMANY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 GERMANY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 333 GERMANY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 334 GERMANY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 335 GERMANY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 336 GERMANY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 337 GERMANY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 338 GERMANY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 GERMANY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 340 GERMANY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 341 GERMANY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 342 GERMANY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 343 GERMANY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 344 GERMANY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 345 GERMANY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 346 GERMANY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 347 GERMANY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 348 GERMANY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 349 GERMANY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 350 GERMANY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 351 GERMANY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 352 GERMANY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 353 GERMANY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 354 GERMANY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 355 GERMANY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 356 GERMANY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 357 GERMANY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 358 GERMANY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 359 GERMANY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 360 GERMANY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 361 GERMANY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 362 GERMANY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 363 FRANCE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 364 FRANCE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 365 FRANCE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 366 FRANCE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 367 FRANCE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 368 FRANCE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 FRANCE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 370 FRANCE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 371 FRANCE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 372 FRANCE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 373 FRANCE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 374 FRANCE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 375 FRANCE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 376 FRANCE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 FRANCE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 378 FRANCE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 379 FRANCE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 380 FRANCE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 381 FRANCE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 382 FRANCE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 383 FRANCE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 384 FRANCE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 385 FRANCE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 386 FRANCE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 387 FRANCE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 388 FRANCE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 389 FRANCE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 390 FRANCE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 391 FRANCE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 392 FRANCE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 393 FRANCE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 394 FRANCE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 395 FRANCE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 396 FRANCE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 397 FRANCE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 398 FRANCE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 399 FRANCE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 400 FRANCE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 401 FRANCE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 402 FRANCE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 403 FRANCE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 404 FRANCE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 405 FRANCE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 406 FRANCE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 407 FRANCE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 408 FRANCE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 409 FRANCE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 410 FRANCE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 411 FRANCE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 412 U.K. ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 413 U.K. INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 414 U.K. NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 415 U.K. M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 416 U.K. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 417 U.K. HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 418 U.K. REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 419 U.K. NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 420 U.K. NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 421 U.K. INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 422 U.K. NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 423 U.K. INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 424 U.K. GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 425 U.K. PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 426 U.K. HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 427 U.K. NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 428 U.K. NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 429 U.K. NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 430 U.K. NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 431 U.K. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 432 U.K. MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 433 U.K. HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 434 U.K. DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 435 U.K. ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 436 U.K. VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 437 U.K. DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 438 U.K. RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 439 U.K. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 440 U.K. FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 441 U.K. ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 442 U.K. GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 443 U.K. CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 444 U.K. ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 445 U.K. ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 446 U.K. ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 447 U.K. SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 448 U.K. SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 449 U.K. LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 450 U.K. TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 451 U.K. SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 452 U.K. LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 453 U.K. SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 454 U.K. PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 455 U.K.CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 456 U.K. NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 457 U.K. ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 458 U.K. ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 459 U.K. ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 460 HUNGARY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 461 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 462 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 463 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 464 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 465 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 466 HUNGARY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 467 HUNGARY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 468 HUNGARY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 469 HUNGARY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 470 HUNGARY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 471 HUNGARY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 472 HUNGARY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 473 HUNGARY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 474 HUNGARY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 475 HUNGARY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 476 HUNGARY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 477 HUNGARY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 478 HUNGARY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 479 HUNGARY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 480 HUNGARY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 481 HUNGARY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 482 HUNGARY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 483 HUNGARY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 484 HUNGARY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 485 HUNGARY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 486 HUNGARY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 487 HUNGARY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 488 HUNGARY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 489 HUNGARY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 490 HUNGARY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 491 HUNGARY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 492 HUNGARY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 493 HUNGARY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 494 HUNGARY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 495 HUNGARY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 496 HUNGARY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 497 HUNGARY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 498 HUNGARY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 499 HUNGARY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 500 HUNGARY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 501 HUNGARY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 502 HUNGARY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 503 HUNGARY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 504 HUNGARY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 505 HUNGARY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 506 HUNGARY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 507 HUNGARY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 508 HUNGARY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 509 HUNGARY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 510 HUNGARY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 511 LITHUANIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 512 LITHUANIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 513 LITHUANIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 514 LITHUANIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 515 LITHUANIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 516 LITHUANIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 517 LITHUANIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 518 LITHUANIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 519 LITHUANIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 520 LITHUANIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 521 LITHUANIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 522 LITHUANIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 523 LITHUANIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 524 LITHUANIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 525 LITHUANIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 526 LITHUANIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 527 LITHUANIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 528 LITHUANIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 529 LITHUANIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 530 LITHUANIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 531 LITHUANIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 532 LITHUANIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 533 LITHUANIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 534 LITHUANIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 535 LITHUANIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 536 LITHUANIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 537 LITHUANIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 538 LITHUANIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 539 LITHUANIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 540 LITHUANIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 541 LITHUANIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 542 LITHUANIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 543 LITHUANIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 544 LITHUANIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 545 LITHUANIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 546 LITHUANIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 547 LITHUANIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 548 LITHUANIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 549 LITHUANIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 550 LITHUANIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 551 LITHUANIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 552 LITHUANIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 553 LITHUANIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 554 LITHUANIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 555 LITHUANIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 556 LITHUANIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 557 LITHUANIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 558 LITHUANIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 559 LITHUANIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 560 AUSTRIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 561 AUSTRIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 562 AUSTRIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 563 AUSTRIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 564 AUSTRIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 565 AUSTRIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 566 AUSTRIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 567 AUSTRIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 568 AUSTRIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 569 AUSTRIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 570 AUSTRIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 571 AUSTRIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 572 AUSTRIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 573 AUSTRIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 574 AUSTRIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 575 AUSTRIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 576 AUSTRIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 577 AUSTRIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 578 AUSTRIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 579 AUSTRIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 580 AUSTRIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 581 AUSTRIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 582 AUSTRIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 583 AUSTRIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 584 AUSTRIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 585 AUSTRIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 586 AUSTRIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 587 AUSTRIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 588 AUSTRIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 589 AUSTRIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 590 AUSTRIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 591 AUSTRIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 592 AUSTRIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 593 AUSTRIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 594 AUSTRIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 595 AUSTRIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 596 AUSTRIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 597 AUSTRIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 598 AUSTRIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 599 AUSTRIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 600 AUSTRIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 601 AUSTRIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 602 AUSTRIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 603 AUSTRIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 604 AUSTRIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 605 AUSTRIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 606 AUSTRIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 607 AUSTRIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 608 AUSTRIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 609 IRELAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 610 IRELAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 611 IRELAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 612 IRELAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 613 IRELAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 614 IRELAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 615 IRELAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 616 IRELAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 617 IRELAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 618 IRELAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 619 IRELAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 620 IRELAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 621 IRELAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 622 IRELAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 623 IRELAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 624 IRELAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 625 IRELAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 626 IRELAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 627 IRELAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 628 IRELAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 629 IRELAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 630 IRELAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 631 IRELAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 632 IRELAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 633 IRELAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 634 IRELAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 635 IRELAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 636 IRELAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 637 IRELAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 638 IRELAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 639 IRELAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 640 IRELAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 641 IRELAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 642 IRELAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 643 IRELAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 644 IRELAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 645 IRELAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 646 IRELAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 647 IRELAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 648 IRELAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 649 IRELAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 650 IRELAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 651 IRELAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 652 IRELAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 653 IRELAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 654 IRELAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 655 IRELAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 656 IRELAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 657 IRELAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 658 NORWAY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 659 NORWAY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 660 NORWAY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 661 NORWAY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 662 NORWAY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 663 NORWAY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 664 NORWAY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 665 NORWAY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 666 NORWAY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 667 NORWAY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 668 NORWAY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 669 NORWAY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 670 NORWAY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 671 NORWAY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 672 NORWAY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 673 NORWAY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 674 NORWAY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 675 NORWAY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 676 NORWAY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 677 NORWAY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 678 NORWAY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 679 NORWAY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 680 NORWAY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 681 NORWAY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 682 NORWAY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 683 NORWAY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 684 NORWAY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 685 NORWAY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 686 NORWAY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 687 NORWAY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 688 NORWAY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 689 NORWAY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 690 NORWAY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 691 NORWAY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 692 NORWAY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 693 NORWAY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 694 NORWAY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 695 NORWAY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 696 NORWAY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 697 NORWAY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 698 NORWAY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 699 NORWAY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 700 NORWAY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 701 NORWAY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 702 NORWAY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 703 NORWAY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 704 NORWAY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 705 NORWAY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 706 NORWAY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 707 POLAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 708 POLAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 709 POLAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 710 POLAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 711 POLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 712 POLAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 713 POLAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 714 POLAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 715 POLAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 716 POLAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 717 POLAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 718 POLAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 719 POLAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 720 POLAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 721 POLAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 722 POLAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 723 POLAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 724 POLAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 725 POLAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 726 POLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 727 POLAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 728 POLAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 729 POLAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 730 POLAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 731 POLAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 732 POLAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 733 POLAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 734 POLAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 735 POLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 736 POLAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 737 POLAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 738 POLAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 739 POLAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 740 POLAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 741 POLAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 742 POLAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 743 POLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 744 POLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 745 POLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 746 POLAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 747 POLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 748 POLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 749 POLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 750 POLAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 751 POLAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 752 POLAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 753 POLAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 754 POLAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 755 POLAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 756 ITALY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 757 ITALY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 758 ITALY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 759 ITALY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 760 ITALY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 761 ITALY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 762 ITALY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 763 ITALY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 764 ITALY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 765 ITALY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 766 ITALY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 767 ITALY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 768 ITALY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 769 ITALY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 770 ITALY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 771 ITALY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 772 ITALY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 773 ITALY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 774 ITALY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 775 ITALY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 776 ITALY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 777 ITALY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 778 ITALY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 779 ITALY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 780 ITALY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 781 ITALY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 782 ITALY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 783 ITALY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 784 ITALY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 785 ITALY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 786 ITALY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 787 ITALY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 788 ITALY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 789 ITALY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 790 ITALY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 791 ITALY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 792 ITALY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 793 ITALY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 794 ITALY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 795 ITALY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 796 ITALY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 797 ITALY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 798 ITALY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 799 ITALY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 800 ITALY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 801 ITALY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 802 ITALY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 803 ITALY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 804 ITALY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 805 SPAIN ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 806 SPAIN INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 807 SPAIN NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 808 SPAIN M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 809 SPAIN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 810 SPAIN HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 811 SPAIN REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 812 SPAIN NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 813 SPAIN NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 814 SPAIN INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 815 SPAIN NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 816 SPAIN INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 817 SPAIN GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 818 SPAIN PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 819 SPAIN HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 820 SPAIN NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 821 SPAIN NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 822 SPAIN NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 823 SPAIN NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 824 SPAIN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 825 SPAIN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 826 SPAIN HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 827 SPAIN DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 828 SPAIN ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 829 SPAIN HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 830 SPAIN VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 831 SPAIN DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 832 SPAIN RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 833 SPAIN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 834 SPAIN FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 835 SPAIN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 836 SPAIN GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 837 SPAIN CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 838 SPAIN ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 839 SPAIN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 840 SPAIN ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 841 SPAIN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 842 SPAIN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 843 SPAIN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 844 SPAIN TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 845 SPAIN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 846 SPAIN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 847 SPAIN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 848 SPAIN PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 849 SPAIN CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 850 SPAIN NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 851 SPAIN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 852 SPAIN ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 853 SPAIN ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 854 RUSSIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 855 RUSSIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 856 RUSSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 857 RUSSIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 858 RUSSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 859 RUSSIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 860 RUSSIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 861 RUSSIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 862 RUSSIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 863 RUSSIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 864 RUSSIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 865 RUSSIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 866 RUSSIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 867 RUSSIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 868 RUSSIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 869 RUSSIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 870 RUSSIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 871 RUSSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 872 RUSSIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 873 RUSSIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 874 RUSSIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 875 RUSSIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 876 RUSSIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 877 RUSSIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 878 RUSSIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 879 RUSSIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 880 RUSSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 881 RUSSIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 882 RUSSIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 883 RUSSIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 884 RUSSIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 885 RUSSIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 886 RUSSIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 887 RUSSIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 888 RUSSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 889 RUSSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 890 RUSSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 891 RUSSIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 892 RUSSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 893 RUSSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 894 RUSSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 895 RUSSIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 896 RUSSIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 897 RUSSIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 898 RUSSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 899 RUSSIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 900 RUSSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 901 TURKEY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 902 TURKEY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 903 TURKEY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 904 TURKEY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 905 TURKEY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 906 TURKEY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 907 TURKEY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 908 TURKEY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 909 TURKEY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 910 TURKEY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 911 TURKEY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 912 TURKEY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 913 TURKEY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 914 TURKEY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 915 TURKEY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 916 TURKEY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 917 TURKEY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 918 TURKEY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 919 TURKEY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 920 TURKEY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 921 TURKEY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 922 TURKEY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 923 TURKEY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 924 TURKEY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 925 TURKEY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 926 TURKEY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 927 TURKEY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 928 TURKEY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 929 TURKEY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 930 TURKEY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 931 TURKEY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 932 TURKEY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 933 TURKEY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 934 TURKEY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 935 TURKEY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 936 TURKEY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 937 TURKEY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 938 TURKEY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 939 TURKEY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 940 TURKEY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 941 TURKEY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 942 TURKEY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 943 TURKEY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 944 TURKEY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 945 TURKEY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 946 TURKEY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 947 TURKEY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 948 TURKEY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 949 TURKEY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 950 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 951 NETHERLANDS INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 952 NETHERLANDS NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 953 NETHERLANDS M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 954 NETHERLANDS RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 955 NETHERLANDS HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 956 NETHERLANDS REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 957 NETHERLANDS NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 958 NETHERLANDS NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 959 NETHERLANDS INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 960 NETHERLANDS NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 961 NETHERLANDS INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 962 NETHERLANDS GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 963 NETHERLANDS PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 964 NETHERLANDS HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 965 NETHERLANDS NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 966 NETHERLANDS NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 967 NETHERLANDS NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 968 NETHERLANDS NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 969 NETHERLANDS RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 970 NETHERLANDS MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 971 NETHERLANDS HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 972 NETHERLANDS ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 973 NETHERLANDS HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 974 NETHERLANDS VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 975 NETHERLANDS DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 976 NETHERLANDS RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 977 NETHERLANDS RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 978 NETHERLANDS FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 979 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 980 NETHERLANDS GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 981 NETHERLANDS CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 982 NETHERLANDS ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 983 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 984 NETHERLANDS ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 985 NETHERLANDS SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 986 NETHERLANDS SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 987 NETHERLANDS LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 988 NETHERLANDS TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 989 NETHERLANDS SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 990 NETHERLANDS LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 991 NETHERLANDS SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 992 NETHERLANDS PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 993 NETHERLANDS CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 994 NETHERLANDS NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 995 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 996 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 997 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 998 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 999 SWITZERLAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1000 SWITZERLAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1001 SWITZERLAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1002 SWITZERLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1003 SWITZERLAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1004 SWITZERLAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1005 SWITZERLAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1006 SWITZERLAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1007 SWITZERLAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1008 SWITZERLAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1009 SWITZERLAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1010 SWITZERLAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1011 SWITZERLAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1012 SWITZERLAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1013 SWITZERLAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1014 SWITZERLAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1015 SWITZERLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1016 SWITZERLAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1017 SWITZERLAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1018 SWITZERLAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1019 SWITZERLAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1020 SWITZERLAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1021 SWITZERLAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1022 SWITZERLAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1023 SWITZERLAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1024 SWITZERLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1025 SWITZERLAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1026 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1027 SWITZERLAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1028 SWITZERLAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1029 SWITZERLAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1030 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1031 SWITZERLAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1032 SWITZERLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1033 SWITZERLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1034 SWITZERLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1035 SWITZERLAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1036 SWITZERLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1037 SWITZERLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1038 SWITZERLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1039 SWITZERLAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1040 SWITZERLAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1041 SWITZERLAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1042 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1043 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1044 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1045 REST OF EUROPE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1046 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 1047 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1048 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1049 ASIA-PACIFIC NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1050 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1051 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1052 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1053 ASIA-PACIFIC REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1054 ASIA-PACIFIC NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1055 ASIA-PACIFIC NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1056 ASIA-PACIFIC INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1057 ASIA-PACIFIC NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1058 ASIA-PACIFIC INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1059 ASIA-PACIFIC GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1060 ASIA-PACIFIC PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1061 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1062 ASIA-PACIFIC NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1063 ASIA-PACIFIC NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1064 ASIA-PACIFIC NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1065 ASIA-PACIFIC NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1066 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1067 ASIA-PACIFIC MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1068 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1069 ASIA-PACIFIC DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1070 ASIA-PACIFIC ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1071 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1072 ASIA-PACIFIC VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1073 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1074 ASIA-PACIFIC RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1075 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1076 ASIA-PACIFIC FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1077 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1078 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1079 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1080 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1081 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1082 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1083 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1084 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1085 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1086 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1087 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1088 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1089 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1090 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1091 ASIA-PACIFIC CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1092 ASIA-PACIFIC NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1093 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1094 JAPAN ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1095 JAPAN INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1096 JAPAN NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1097 JAPAN M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1098 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1099 JAPAN HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1100 JAPAN REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1101 JAPAN NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1102 JAPAN NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1103 JAPAN INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1104 JAPAN NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1105 JAPAN INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1106 JAPAN GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1107 JAPAN PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1108 JAPAN HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1109 JAPAN NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1110 JAPAN NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1111 JAPAN NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1112 JAPAN NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1113 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1114 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1115 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1116 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1117 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1118 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1119 JAPAN ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1120 JAPAN HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1121 JAPAN VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1122 JAPAN DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1123 JAPAN RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1124 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1125 JAPAN FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1126 JAPAN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1127 JAPAN GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1128 JAPAN CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1129 JAPAN ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1130 JAPAN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1131 JAPAN ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1132 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1133 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1134 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1135 JAPAN TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1136 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1137 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1138 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1139 JAPAN PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1140 JAPAN CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1141 JAPAN NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1142 JAPAN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1143 JAPAN ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1144 JAPAN ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1145 CHINA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1146 CHINA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1147 CHINA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1148 CHINA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1149 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1150 CHINA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1151 CHINA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1152 CHINA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1153 CHINA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1154 CHINA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1155 CHINA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1156 CHINA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1157 CHINA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1158 CHINA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1159 CHINA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1160 CHINA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1161 CHINA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1162 CHINA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1163 CHINA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1164 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1165 CHINA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1166 CHINA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1167 CHINA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1168 CHINA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1169 CHINA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1170 CHINA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1171 CHINA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1172 CHINA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1173 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1174 CHINA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1175 CHINA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1176 CHINA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1177 CHINA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1178 CHINA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1179 CHINA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1180 CHINA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1181 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1182 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1183 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1184 CHINA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1185 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1186 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1187 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1188 CHINA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1189 CHINA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1190 CHINA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1191 CHINA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1192 CHINA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1193 CHINA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1194 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1195 SOUTH KOREA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1196 SOUTH KOREA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1197 SOUTH KOREA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1198 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1199 SOUTH KOREA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1200 SOUTH KOREA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1201 SOUTH KOREA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1202 SOUTH KOREA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1203 SOUTH KOREA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1204 SOUTH KOREA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1205 SOUTH KOREA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1206 SOUTH KOREA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1207 SOUTH KOREA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1208 SOUTH KOREA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1209 SOUTH KOREA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1210 SOUTH KOREA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1211 SOUTH KOREA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1212 SOUTH KOREA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1213 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1214 SOUTH KOREA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1215 SOUTH KOREA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1216 SOUTH KOREA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1217 SOUTH KOREA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1218 SOUTH KOREA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1219 SOUTH KOREA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1220 SOUTH KOREA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1221 SOUTH KOREA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1222 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1223 SOUTH KOREA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1224 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1225 SOUTH KOREA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1226 SOUTH KOREA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1227 SOUTH KOREA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1228 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1229 SOUTH KOREA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1230 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1231 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1232 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1233 SOUTH KOREA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1234 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1235 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1236 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1237 SOUTH KOREA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1238 SOUTH KOREA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1239 SOUTH KOREA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1240 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1241 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1242 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1243 INDIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1244 INDIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1245 INDIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1246 INDIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1247 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1248 INDIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1249 INDIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1250 INDIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1251 INDIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1252 INDIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1253 INDIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1254 INDIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1255 INDIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1256 INDIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1257 INDIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1258 INDIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1259 INDIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1260 INDIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1261 INDIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1262 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1263 INDIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1264 INDIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1265 INDIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1266 INDIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1267 INDIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1268 INDIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1269 INDIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1270 INDIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1271 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1272 INDIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1273 INDIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1274 INDIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1275 INDIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1276 INDIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1277 INDIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1278 INDIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1279 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1280 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1281 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1282 INDIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1283 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1284 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1285 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1286 INDIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1287 INDIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1288 INDIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1289 INDIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1290 INDIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1291 INDIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1292 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1293 AUSTRALIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1294 AUSTRALIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1295 AUSTRALIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1296 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1297 AUSTRALIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1298 AUSTRALIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1299 AUSTRALIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1300 AUSTRALIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1301 AUSTRALIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1302 AUSTRALIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1303 AUSTRALIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1304 AUSTRALIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1305 AUSTRALIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1306 AUSTRALIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1307 AUSTRALIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1308 AUSTRALIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1309 AUSTRALIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1310 AUSTRALIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1311 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1312 AUSTRALIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1313 AUSTRALIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1314 AUSTRALIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1315 AUSTRALIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1316 AUSTRALIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1317 AUSTRALIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1318 AUSTRALIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1319 AUSTRALIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1320 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1321 AUSTRALIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1322 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1323 AUSTRALIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1324 AUSTRALIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1325 AUSTRALIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1326 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1327 AUSTRALIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1328 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1329 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1330 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1331 AUSTRALIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1332 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1333 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1334 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1335 AUSTRALIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1336 AUSTRALIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1337 AUSTRALIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1338 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1339 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1340 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1341 SINGAPORE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1342 SINGAPORE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1343 SINGAPORE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1344 SINGAPORE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1345 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1346 SINGAPORE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1347 SINGAPORE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1348 SINGAPORE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1349 SINGAPORE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1350 SINGAPORE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1351 SINGAPORE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1352 SINGAPORE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1353 SINGAPORE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1354 SINGAPORE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1355 SINGAPORE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1356 SINGAPORE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1357 SINGAPORE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1358 SINGAPORE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1359 SINGAPORE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1360 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1361 SINGAPORE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1362 SINGAPORE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1363 SINGAPORE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1364 SINGAPORE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1365 SINGAPORE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1366 SINGAPORE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1367 SINGAPORE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1368 SINGAPORE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1369 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1370 SINGAPORE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1371 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1372 SINGAPORE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1373 SINGAPORE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1374 SINGAPORE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1375 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1376 SINGAPORE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1377 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1378 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1379 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1380 SINGAPORE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1381 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1382 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1383 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1384 SINGAPORE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1385 SINGAPORE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1386 SINGAPORE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1387 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1388 SINGAPORE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1389 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1390 THAILAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1391 THAILAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1392 THAILAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1393 THAILAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1394 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1395 THAILAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1396 THAILAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1397 THAILAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1398 THAILAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1399 THAILAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1400 THAILAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1401 THAILAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1402 THAILAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1403 THAILAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1404 THAILAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1405 THAILAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1406 THAILAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1407 THAILAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1408 THAILAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1409 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1410 THAILAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1411 THAILAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1412 THAILAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1413 THAILAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1414 THAILAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1415 THAILAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1416 THAILAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1417 THAILAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1418 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1419 THAILAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1420 THAILAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1421 THAILAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1422 THAILAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1423 THAILAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1424 THAILAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1425 THAILAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1426 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1427 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1428 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1429 THAILAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1430 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1431 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1432 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1433 THAILAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1434 THAILAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1435 THAILAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1436 THAILAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1437 THAILAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1438 THAILAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1439 MALAYSIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1440 MALAYSIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1441 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1442 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1443 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1444 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1445 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1446 MALAYSIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1447 MALAYSIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1448 MALAYSIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1449 MALAYSIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1450 MALAYSIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1451 MALAYSIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1452 MALAYSIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1453 MALAYSIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1454 MALAYSIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1455 MALAYSIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1456 MALAYSIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1457 MALAYSIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1458 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1459 MALAYSIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1460 MALAYSIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1461 MALAYSIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1462 MALAYSIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1463 MALAYSIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1464 MALAYSIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1465 MALAYSIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1466 MALAYSIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1467 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1468 MALAYSIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1469 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1470 MALAYSIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1471 MALAYSIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1472 MALAYSIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1473 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1474 MALAYSIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1475 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1476 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1477 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1478 MALAYSIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1479 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1480 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1481 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1482 MALAYSIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1483 MALAYSIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1484 MALAYSIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1485 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1486 MALAYSIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1487 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1488 INDONESIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1489 INDONESIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1490 INDONESIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1491 INDONESIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1492 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1493 INDONESIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1494 INDONESIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1495 INDONESIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1496 INDONESIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1497 INDONESIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1498 INDONESIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1499 INDONESIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1500 INDONESIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1501 INDONESIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1502 INDONESIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1503 INDONESIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1504 INDONESIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1505 INDONESIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1506 INDONESIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1507 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1508 INDONESIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1509 INDONESIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1510 INDONESIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1511 INDONESIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1512 INDONESIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1513 INDONESIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1514 INDONESIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1515 INDONESIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1516 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1517 INDONESIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1518 INDONESIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1519 INDONESIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1520 INDONESIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1521 INDONESIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1522 INDONESIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1523 INDONESIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1524 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1525 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1526 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1527 INDONESIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1528 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1529 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1530 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1531 INDONESIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1532 INDONESIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1533 INDONESIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1534 INDONESIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1535 INDONESIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1536 INDONESIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1537 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1538 PHILIPPINES INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1539 PHILIPPINES NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1540 PHILIPPINES M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1541 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1542 PHILIPPINES HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1543 PHILIPPINES REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1544 PHILIPPINES NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1545 PHILIPPINES INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1546 PHILIPPINES NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1547 PHILIPPINES INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1548 PHILIPPINES GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1549 PHILIPPINES PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1550 PHILIPPINES HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1551 PHILIPPINES NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1552 PHILIPPINES NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1553 PHILIPPINES NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1554 PHILIPPINES NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1555 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1556 PHILIPPINES MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1557 PHILIPPINES HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1558 PHILIPPINES DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1559 PHILIPPINES ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1560 PHILIPPINES HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1561 PHILIPPINES VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1562 PHILIPPINES DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1563 PHILIPPINES RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1564 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1565 PHILIPPINES FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1566 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1567 PHILIPPINES GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1568 PHILIPPINES CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1569 PHILIPPINES ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1570 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1571 PHILIPPINES ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1572 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1573 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1574 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1575 PHILIPPINES TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1576 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1577 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1578 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1579 PHILIPPINES PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1580 PHILIPPINES CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1581 PHILIPPINES NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1582 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1583 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1584 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1585 VIETNAM ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1586 VIETNAM INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1587 VIETNAM NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1588 VIETNAM M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1589 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1590 VIETNAM HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1591 VIETNAM REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1592 VIETNAM NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1593 VIETNAM NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1594 VIETNAM INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1595 VIETNAM NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1596 VIETNAM INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1597 VIETNAM GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1598 VIETNAM PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1599 VIETNAM HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1600 VIETNAM NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1601 VIETNAM NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1602 VIETNAM NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1603 VIETNAM NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1604 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1605 VIETNAM MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1606 VIETNAM HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1607 VIETNAM DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1608 VIETNAM ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1609 VIETNAM HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1610 VIETNAM VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1611 VIETNAM DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1612 VIETNAM RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1613 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1614 VIETNAM FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1615 VIETNAM ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1616 VIETNAM GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1617 VIETNAM CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1618 VIETNAM ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1619 VIETNAM ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1620 VIETNAM ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1621 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1622 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1623 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1624 VIETNAM TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1625 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1626 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1627 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1628 VIETNAM PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1629 VIETNAM CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1630 VIETNAM NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1631 VIETNAM ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1632 VIETNAM ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1633 VIETNAM ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1634 REST OF ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1635 SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 1636 SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1637 SOUTH AMERICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1638 SOUTH AMERICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1639 SOUTH AMERICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1640 SOUTH AMERICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1641 SOUTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1642 SOUTH AMERICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1643 SOUTH AMERICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1644 SOUTH AMERICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1645 SOUTH AMERICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1646 SOUTH AMERICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1647 SOUTH AMERICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1648 SOUTH AMERICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1649 SOUTH AMERICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1650 SOUTH AMERICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1651 SOUTH AMERICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1652 SOUTH AMERICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1653 SOUTH AMERICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1654 SOUTH AMERICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1655 SOUTH AMERICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1656 SOUTH AMERICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1657 SOUTH AMERICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1658 SOUTH AMERICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1659 SOUTH AMERICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1660 SOUTH AMERICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1661 SOUTH AMERICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1662 SOUTH AMERICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1663 SOUTH AMERICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1664 SOUTH AMERICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1665 SOUTH AMERICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1666 SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1667 SOUTH AMERICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1668 SOUTH AMERICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1669 SOUTH AMERICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1670 SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1671 SOUTH AMERICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1672 SOUTH AMERICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1673 SOUTH AMERICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1674 SOUTH AMERICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1675 SOUTH AMERICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1676 SOUTH AMERICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1677 SOUTH AMERICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1678 SOUTH AMERICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1679 SOUTH AMERICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1680 SOUTH AMERICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1681 SOUTH AMERICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1682 SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1683 SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1684 SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1685 BRAZIL ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1686 BRAZIL INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1687 BRAZIL NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1688 BRAZIL M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1689 BRAZIL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1690 BRAZIL HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1691 BRAZIL REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1692 BRAZIL NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1693 BRAZIL NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1694 BRAZIL INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1695 BRAZIL NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1696 BRAZIL INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1697 BRAZIL GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1698 BRAZIL PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1699 BRAZIL HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1700 BRAZIL NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1701 BRAZIL NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1702 BRAZIL NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1703 BRAZIL NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1704 BRAZIL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1705 BRAZIL MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1706 BRAZIL HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1707 BRAZIL DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1708 BRAZIL ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1709 BRAZIL HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1710 BRAZIL VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1711 BRAZIL DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1712 BRAZIL RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1713 BRAZIL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1714 BRAZIL FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1715 BRAZIL ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1716 BRAZIL GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1717 BRAZIL CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1718 BRAZIL ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1719 BRAZIL ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1720 BRAZIL ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1721 BRAZIL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1722 BRAZIL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1723 BRAZIL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1724 BRAZIL TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1725 BRAZIL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1726 BRAZIL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1727 BRAZIL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1728 BRAZIL PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1729 BRAZIL CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1730 BRAZIL NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1731 BRAZIL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1732 BRAZIL ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1733 BRAZIL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1734 ARGENTINA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1735 ARGENTINA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1736 ARGENTINA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1737 ARGENTINA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1738 ARGENTINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1739 ARGENTINA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1740 ARGENTINA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1741 ARGENTINA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1742 ARGENTINA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1743 ARGENTINA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1744 ARGENTINA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1745 ARGENTINA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1746 ARGENTINA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1747 ARGENTINA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1748 ARGENTINA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1749 ARGENTINA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1750 ARGENTINA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1751 ARGENTINA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1752 ARGENTINA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1753 ARGENTINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1754 ARGENTINA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1755 ARGENTINA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1756 ARGENTINA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1757 ARGENTINA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1758 ARGENTINA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1759 ARGENTINA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1760 ARGENTINA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1761 ARGENTINA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1762 ARGENTINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1763 ARGENTINA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1764 ARGENTINA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1765 ARGENTINA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1766 ARGENTINA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1767 ARGENTINA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1768 ARGENTINA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1769 ARGENTINA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1770 ARGENTINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1771 ARGENTINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1772 ARGENTINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1773 ARGENTINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1774 ARGENTINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1775 ARGENTINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1776 ARGENTINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1777 ARGENTINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1778 ARGENTINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1779 ARGENTINA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1780 ARGENTINA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1781 ARGENTINA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1782 ARGENTINA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1783 ARGENTINA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1784 ARGENTINA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1785 PERU ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1786 PERU INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1787 PERU NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1788 PERU M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1789 PERU RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1790 PERU HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1791 PERU REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1792 PERU NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1793 PERU NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1794 PERU INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1795 PERU NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1796 PERU INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1797 PERU GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1798 PERU PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1799 PERU HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1800 PERU NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1801 PERU NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1802 PERU NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1803 PERU NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1804 PERU RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1805 PERU MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1806 PERU HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1807 PERU DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1808 PERU ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1809 PERU HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1810 PERU VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1811 PERU DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1812 PERU RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1813 PERU RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1814 PERU FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1815 PERU ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1816 PERU GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1817 PERU CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1818 PERU ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1819 PERU ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1820 PERU ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1821 PERU SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1822 PERU SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1823 PERU LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1824 PERU TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1825 PERU SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1826 PERU LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1827 PERU SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1828 PERU PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1829 PERU CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1830 PERU NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1831 PERU ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1832 PERU ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1833 PERU ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1834 REST OF SOUTH AMERICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1835 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 1836 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1837 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1838 MIDDLE EAST AND AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1839 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1840 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1841 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1842 MIDDLE EAST AND AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1843 MIDDLE EAST AND AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1844 MIDDLE EAST AND AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1845 MIDDLE EAST AND AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1846 MIDDLE EAST AND AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1847 MIDDLE EAST AND AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1848 MIDDLE EAST AND AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1849 MIDDLE EAST AND AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1850 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1851 MIDDLE EAST AND AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1852 MIDDLE EAST AND AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1853 MIDDLE EAST AND AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1854 MIDDLE EAST AND AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1855 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1856 MIDDLE EAST AND AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1857 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1858 MIDDLE EAST AND AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1859 MIDDLE EAST AND AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1860 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1861 MIDDLE EAST AND AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1862 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1863 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1864 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1865 MIDDLE EAST AND AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1866 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1867 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1868 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1869 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1870 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1871 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1872 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1873 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1874 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1875 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1876 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1877 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1878 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1879 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1880 MIDDLE EAST AND AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1881 MIDDLE EAST AND AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1882 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1883 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1884 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1885 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1886 SOUTH AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1887 SOUTH AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1888 SOUTH AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1889 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1890 SOUTH AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1891 SOUTH AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1892 SOUTH AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1893 SOUTH AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1894 SOUTH AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1895 SOUTH AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1896 SOUTH AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1897 SOUTH AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1898 SOUTH AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1899 SOUTH AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1900 SOUTH AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1901 SOUTH AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1902 SOUTH AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1903 SOUTH AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1904 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1905 SOUTH AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1906 SOUTH AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1907 SOUTH AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1908 SOUTH AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1909 SOUTH AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1910 SOUTH AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1911 SOUTH AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1912 SOUTH AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1913 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1914 SOUTH AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1915 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1916 SOUTH AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1917 SOUTH AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1918 SOUTH AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1919 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1920 SOUTH AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1921 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1922 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1923 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1924 SOUTH AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1925 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1926 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1927 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1928 SOUTH AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1929 SOUTH AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1930 SOUTH AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1931 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1932 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1933 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1934 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1935 SAUDI ARABIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1936 SAUDI ARABIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1937 SAUDI ARABIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1938 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1939 SAUDI ARABIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1940 SAUDI ARABIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1941 SAUDI ARABIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1942 SAUDI ARABIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1943 SAUDI ARABIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1944 SAUDI ARABIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1945 SAUDI ARABIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1946 SAUDI ARABIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1947 SAUDI ARABIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1948 SAUDI ARABIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1949 SAUDI ARABIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1950 SAUDI ARABIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1951 SAUDI ARABIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1952 SAUDI ARABIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1953 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1954 SAUDI ARABIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1955 SAUDI ARABIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1956 SAUDI ARABIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1957 SAUDI ARABIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1958 SAUDI ARABIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1959 SAUDI ARABIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1960 SAUDI ARABIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1961 SAUDI ARABIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1962 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1963 SAUDI ARABIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1964 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1965 SAUDI ARABIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1966 SAUDI ARABIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1967 SAUDI ARABIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 1968 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1969 SAUDI ARABIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1970 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1971 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1972 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1973 SAUDI ARABIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1974 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1975 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1976 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1977 SAUDI ARABIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1978 SAUDI ARABIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1979 SAUDI ARABIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 1980 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1981 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 1982 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 1983 U.A.E ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 1984 U.A.E INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1985 U.A.E NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1986 U.A.E M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1987 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1988 U.A.E HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1989 U.A.E REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1990 U.A.E NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1991 U.A.E NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1992 U.A.E INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1993 U.A.E NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1994 U.A.E INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1995 U.A.E GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1996 U.A.E PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1997 U.A.E HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1998 U.A.E NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 1999 U.A.E NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2000 U.A.E NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2001 U.A.E NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2002 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2003 U.A.E MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2004 U.A.E HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2005 U.A.E DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2006 U.A.E ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2007 U.A.E HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2008 U.A.E VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2009 U.A.E DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2010 U.A.E RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2011 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2012 U.A.E FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2013 U.A.E ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2014 U.A.E GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2015 U.A.E CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2016 U.A.E ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2017 U.A.E ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2018 U.A.E ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2019 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2020 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2021 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2022 U.A.E TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2023 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2024 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2025 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2026 U.A.E PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2027 UAECONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2028 U.A.E NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2029 U.A.E ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2030 U.A.E ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 2031 U.A.E ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 2032 EGYPT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 2033 EGYPT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2034 EGYPT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2035 EGYPT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2036 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2037 EGYPT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2038 EGYPT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2039 EGYPT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2040 EGYPT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2041 EGYPT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2042 EGYPT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2043 EGYPT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2044 EGYPT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2045 EGYPT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2046 EGYPT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2047 EGYPT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2048 EGYPT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2049 EGYPT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2050 EGYPT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2051 EGYPT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2052 EGYPT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2053 EGYPT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2054 EGYPT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2055 EGYPT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2056 EGYPT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2057 EGYPT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2058 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2059 EGYPT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2060 EGYPT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2061 EGYPT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2062 EGYPT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2063 EGYPT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2064 EGYPT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2065 EGYPT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2066 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2067 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2068 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2069 EGYPT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2070 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2071 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2072 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2073 EGYPT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2074 EGYPT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2075 EGYPT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2076 EGYPT ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2077 EGYPT ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 2078 EGYPT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 2079 KUWAIT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 2080 KUWAIT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2081 KUWAIT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2082 KUWAIT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2083 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2084 KUWAIT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2085 KUWAIT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2086 KUWAIT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2087 KUWAIT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2088 KUWAIT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2089 KUWAIT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2090 KUWAIT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2091 KUWAIT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2092 KUWAIT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2093 KUWAIT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2094 KUWAIT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2095 KUWAIT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2096 KUWAIT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2097 KUWAIT NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2098 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2099 KUWAIT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2100 KUWAIT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2101 KUWAIT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2102 KUWAIT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2103 KUWAIT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2104 KUWAIT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2105 KUWAIT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2106 KUWAIT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2107 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2108 KUWAIT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2109 KUWAIT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2110 KUWAIT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2111 KUWAIT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2112 KUWAIT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2113 KUWAIT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2114 KUWAIT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2115 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2116 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2117 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2118 KUWAIT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2119 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2120 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2121 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2122 KUWAIT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2123 KUWAIT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2124 KUWAIT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2125 KUWAIT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 2126 ISRAEL ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 2127 ISRAEL INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2128 ISRAEL NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2129 ISRAEL M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2130 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2131 ISRAEL HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2132 ISRAEL REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2133 ISRAEL NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2134 ISRAEL NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2135 ISRAEL INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2136 ISRAEL NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2137 ISRAEL INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2138 ISRAEL GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2139 ISRAEL PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2140 ISRAEL HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2141 ISRAEL NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2142 ISRAEL NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2143 ISRAEL NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2144 ISRAEL NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2145 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2146 ISRAEL MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2147 ISRAEL HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2148 ISRAEL DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2149 ISRAEL ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2150 ISRAEL HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2151 ISRAEL VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2152 ISRAEL DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2153 ISRAEL RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2154 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2155 ISRAEL FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2156 ISRAEL ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2157 ISRAEL GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2158 ISRAEL CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2159 ISRAEL ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 2160 ISRAEL ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2161 ISRAEL ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2162 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2163 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2164 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2165 ISRAEL TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2166 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2167 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2168 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2169 ISRAEL PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2170 ISRAEL CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2171 ISRAEL NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2172 ISRAEL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 2173 ISRAEL ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 2174 ISRAEL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 2175 REST OF MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)